Loading...
•
Dec 31, 2019
Incyte Q4 2019 Earnings Report
Incyte reported strong revenue growth driven by Jakafi demand and provided 2020 financial guidance.
Key Takeaways
Incyte reported its Q4 and year-end financial results for 2019, highlighting strong revenue growth driven by Jakafi. The company also announced 2020 financial guidance and provided updates on its key clinical programs.
Revenue growth was strong, driven by robust demand for Jakafi across all three indications.
Initial results from the Phase 3 TRuE-AD program were successful, with plans to submit an NDA for ruxolitinib cream in Q4 2020.
FDA decisions on potential approvals of pemigatinib and capmatinib are expected later in the year.
A global collaboration with MorphoSys for tafasitamab was announced, pending clearance by antitrust authorities.
Incyte
Incyte
Incyte Revenue by Segment
Incyte Revenue by Geographic Location
Revenue by Segment
Jakafi Revenue
CapyFin.comIclusig Revenue
CapyFin.comRevenue by Geographic Location
Jakavi Royalty Revenue
CapyFin.comOlumiant Royalty Revenue
CapyFin.com Forward Guidance
Incyte provided its 2020 financial guidance, excluding the impact of the MorphoSys collaboration and any potential future strategic transactions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income